What guideline‑directed medications should be initiated for heart failure?

Guideline-Directed Medical Therapy for Heart Failure with Reduced Ejection Fraction

For heart failure with reduced ejection fraction (HFrEF), initiate all four foundational medication classes—ARNI (or ACEi/ARB if ARNI not feasible), beta-blocker, mineralocorticoid receptor antagonist (MRA), and SGLT2 inhibitor—simultaneously or in rapid sequence at low doses, then uptitrate to target doses regardless of symptom improvement. 1, 2

The Four Pillars of HFrEF Therapy

1. Renin-Angiotensin System Inhibition (Class I, Level A)

First-line choice: Angiotensin Receptor-Neprilysin Inhibitor (ARNi)

• Sacubitril-valsartan is the preferred agent for NYHA class II-III symptoms 2
• Start: 49 mg sacubitril/51 mg valsartan twice daily
• Target: 97 mg sacubitril/103 mg valsartan twice daily 1
• Provides 16% relative risk reduction in mortality beyond ACEi therapy 1

Alternative options when ARNi not feasible:

• ACE inhibitors (Class I, Level A) 2:

  • Enalapril: Start 2.5 mg twice daily, target 10-20 mg twice daily
  • Lisinopril: Start 2.5-5 mg daily, target 20-40 mg daily
  • Ramipril: Start 1.25-2.5 mg daily, target 10 mg daily 1

• ARBs (Class I, Level A) - only if ACEi causes cough/angioedema and ARNi not feasible 2:

  • Losartan: Start 25-50 mg daily, target 50-150 mg daily
  • Valsartan: Start 20-40 mg daily, target 160 mg twice daily 1

2. Beta-Blockers (Class I, Level A)

Use only the three evidence-based agents 2:

• Carvedilol: Start 3.125 mg twice daily, target 25-50 mg twice daily
• Metoprolol succinate (extended-release): Start 12.5-25 mg daily, target 200 mg daily
• Bisoprolol: Start 1.25 mg daily, target 10 mg daily 1

Beta-blockers provide the largest mortality benefit with 34% relative risk reduction and NNT of 28 over 12 months—the most powerful single drug class effect 1.

3. Mineralocorticoid Receptor Antagonists (Class I, Level A)

Initiate if eGFR >30 mL/min/1.73 m² and appropriate potassium levels 2:

• Spironolactone: Start 12.5-25 mg daily, target 25-50 mg daily
• Eplerenone: Start 25 mg daily, target 50 mg daily 1

MRAs provide 30% relative risk reduction in mortality with NNT of 18 over 24 months 1.

4. SGLT2 Inhibitors (Class I, Level A)

Initiate regardless of diabetes status 2:

• Dapagliflozin: 10 mg once daily (no titration needed)
• Empagliflozin: 10 mg once daily (no titration needed) 1

SGLT2 inhibitors provide 17% relative risk reduction in mortality with benefits across the entire ejection fraction spectrum 1, 3.

Implementation Strategy

Simultaneous vs. Sequential Initiation

Start all four medications simultaneously at initial low doses rather than waiting to achieve target dosing before adding the next medication 2, 4. This approach is supported by recent evidence showing:

• Rapid sequence initiation is safe and effective 4, 5
• In-hospital initiation during acute decompensation is feasible and well-tolerated 6
• The "high-intensity care" strategy with rapid uptitration improves outcomes 3

Uptitration Protocol

Increase doses to trial-proven target doses even if symptoms improve at lower doses 1. The target doses established efficacy and safety in clinical trials—lower doses may not provide full mortality benefit.

Monitor during uptitration:

• Blood pressure (avoid symptomatic hypotension)
• Heart rate (target >50-60 bpm with beta-blockers)
• Renal function (creatinine increases up to 30% acceptable if stable) 6
• Potassium (monitor closely with MRAs, especially if eGFR 30-60)

Additional Therapies for Specific Populations

For Self-Identified Black Patients (Class I, Level A)

Hydralazine-isosorbide dinitrate in addition to standard therapy 2:

• Start: 20 mg isosorbide dinitrate/37.5 mg hydralazine three times daily
• Target: 40 mg isosorbide dinitrate/75 mg hydralazine three times daily 1
• Provides 43% relative risk reduction in mortality (NNT = 21 over 10 months) 1

For Persistent Symptoms Despite Quadruple Therapy

Ivabradine (if sinus rhythm, heart rate ≥70 bpm, already on beta-blocker):

• Start: 5 mg twice daily
• Target: 7.5 mg twice daily 1

Vericiguat (for worsening HF despite GDMT):

• Start: 2.5 mg daily
• Target: 10 mg daily 1, 3

Digoxin (for persistent symptoms):

• Dose: 0.125-0.25 mg daily
• Target serum level: 0.5-0.9 ng/mL 1

Heart Failure with Mildly Reduced or Preserved Ejection Fraction (HFmrEF/HFpEF)

For EF >40%, the evidence base is more limited but growing 3:

Foundational therapy:

• SGLT2 inhibitors (Class 2a recommendation for HFmrEF) 2, 3
• Non-steroidal MRAs (finerenone) show benefit 3

Phenotype-specific adjunctive therapy:

• GLP-1 receptor agonists (semaglutide 2.4 mg weekly) for obesity-related HFpEF—improves quality of life and 6-minute walk distance 3
• ARNi may benefit patients with EF below normal 4

Critical Implementation Pitfalls to Avoid

1. Clinical inertia: Don't delay initiation due to unfounded fears—evidence shows safety of rapid implementation 5
2. Stopping at symptom improvement: Continue uptitration to target doses even when patients feel better 1
3. Sequential delays: Don't wait months between adding each medication class—simultaneous initiation is safe 4
4. Telemedicine limitations: Greater telemedicine use correlates with reduced GDMT initiation—ensure guideline-concordant care regardless of visit modality 7
5. Age discrimination: Older adults (≥75, even ≥90 years) benefit equally from GDMT—age alone is not a contraindication 8

Mortality Benefits Summary

When comparing standardized NNT over 36 months, the hierarchy of benefit is 1:

• Beta-blockers: NNT = 9
• MRAs: NNT = 6
• Hydralazine-nitrate (Black patients): NNT = 7
• ACEi/ARB: NNT = 26
• ARNi (incremental to ACEi): NNT = 27
• SGLT2i: NNT = 22

The combination of all four pillars provides additive mortality reduction far exceeding any single agent 9, 4.